Skip to main content
Clinical Trials/CTRI/2010/091/000120
CTRI/2010/091/000120
Completed
Phase 3

Evaluation of efficacy and safety of butoconazole versus clotrimazole in the treatment of vulvovaginal candidiasis: a randomized, open label, active controlled, multicentric study.

Sun Pharmaceutical Industries Ltd.0 sites200 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Sun Pharmaceutical Industries Ltd.
Enrollment
200
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\. Female patients aged between 18 and 65 years.
  • 2\. Has a primary diagnosis of vulvovaginal candidiasis.
  • 3\. Patient willing to give their informed consent.

Exclusion Criteria

  • 1\. Pregnant, lactating women or women of childbearing age who are not using an acceptable method of birth control.
  • 2\. Patients with vaginal trichomonas infection or clue cells of Gardnerella vaginalis vaginitis.
  • 3\. Patients having history of recurrent vulvovaginal candidiasis, defined as occurrence of four or more than four episodes in the previous 12 months.
  • 4\. Patients having hypersensitivity to imidazole derivatives.
  • 5\. Patients on the treatment with an oral or intravaginal antifungal medication during a week before enrollment.
  • 6\. Patients on therapy with antibiotics, systemic antimycotics, corticosteroids, or immunosuppressive drugs.
  • 7\. Menstruating patients or patients expecting menses during treatment period.

Outcomes

Primary Outcomes

Not specified

Similar Trials